Paz-Bailey, G; Ramaswamy, M; Hawkes, SJ; Geretti, AM (2007) Herpes simplex virus type 2: epidemiology and management options in developing countries. Sexually transmitted infections, 83 (1). pp. 16-22. ISSN 1368-4973 DOI: https://doi.org/10.1136/sti.2006.020966

Downloaded from: http://researchonline.lshtm.ac.uk/6451/

DOI: 10.1136/sti.2006.020966
Herpes simplex virus type 2: epidemiology and management options in developing countries

G Paz-Bailey, M Ramaswamy, S J Hawkes, A M Geretti

Genital herpes simplex virus type 2 (HSV2) is highly prevalent worldwide and an increasingly important cause of genital ulcer disease (GUD). Continued HSV2 transmission is facilitated by the large number of undiagnosed cases, the frequency of atypical disease and the occurrence of asymptomatic shedding. The lack of easy, affordable diagnostic methods and specific antiviral treatment in countries with low and middle income is of great concern, given the ability of GUD to enhance HIV transmission and acquisition. With rising HSV2 prevalence contributing to an increase in the proportion of GUD attributed to genital herpes in high-HIV prevalence settings, a safe and effective HSV vaccine is urgently needed. Meanwhile, multifaceted interventions are required to improve recognition of genital herpes, to prevent its spread and also to prevent its potential to promote HIV transmission in developing countries.

HSV2 EPIDEMIOLOGY

Few countries have population-based national estimates of HSV2 that allow the estimation of seroprevalence trends. In the US, a representative national sample of the population aged >12 years indicated that age-adjusted HSV2 prevalence has increased from 16.4% to 21.7% of adults from 1976 to 1994. European cross-sectional surveys conducted between 1989 and 2000 found that age-standardised HSV2 seroprevalence ranged from 4% in England and Wales to 24% in Bulgaria.

Compared with developing countries, substantially higher rates of HSV2 have been observed in sub-Saharan Africa, with age-adjusted prevalences in adults ranging from 30% to 80% in women and 10% to 50% in men (fig 1). In South America, available data are mainly for women, in whom HSV2 prevalence ranges from 20% to 40%. Prevalence in the general population in Asian countries shows lower values, from 10% to 30%.

The changing epidemiology of GUD

The prevalence and aetiology of GUD in different geographical regions and populations in Africa seem to vary widely, and are also changing over time. Studies on GUD in developing countries published before 1995 identified syphilis and chancroid as the main causes of GUD (table 1). In resource-poor nations, the spread of HIV and factors such as enhanced case identification and treatment for bacterial GUD since 1990 seem to have resulted in altered epidemic patterns of sexually transmitted infections (STIs). Among studies conducted during the past 10 years, HSV2 has been reported as an important cause of GUD in Africa, South East Asia and Latin America. In at least seven locations in Africa where longitudinal data are available, there is evidence of a shift in the aetiology of GUD towards HSV2 (table 1). For example, cross-sectional studies among miners in South Africa reported that the

Abbreviations: GUD, genital ulcer disease; HSV, herpes simplex virus; PCR, polymerase chain reaction; STI, sexually transmitted infection; WHO, World Health Organization
proportion of ulcers due to herpes increased from 3% in 1986 to 17% in 1994 and to 36% in 1998. Paz-Bailey et al reported similar findings from Botswana, where 24% of GUD among patients with STIs was due to HSV2 in 1993, increasing to 60% in 2002. In Botswana, the increases in HSV2 were still marked after adjusting the prevalence for the differences in sensitivity and specificity of diagnostic tests used in 1993 and 2002.

Possible explanations for the changes in GUD aetiology include changes in laboratory techniques, HIV-attributable mortality among high-risk groups, behavioural change, improved syndromic management and increase in antibiotic use. Changes in laboratory techniques, including availability of more sensitive tests such as polymerase chain reaction (PCR), may explain some of the differences but cannot account for all the observed changes in prevalence. HIV-attributable mortality might disproportionately affect the prevalence of chancroid, which heavily relies on core groups to persist. In contrast, owing to its longer duration of infection, HSV2 does not rely on people at high risk to spread and is less influenced by the differential mortality associated with AIDS. Syndromic management was implemented in several countries in Africa in the early 1990s, and widespread use of antibiotics, together with mandatory serological testing for syphilis, may have contributed to a decrease in the prevalence of syphilis and other STIs.

HSV2 AND HIV

An increasing body of literature suggests that HIV and HSV2 manifest bidirectional interactions. Clinical, biological and epidemiological studies support the hypothesis that HSV2 increases the efficiency of HIV acquisition and transmission. Similarly, HIV may increase susceptibility to HSV2, HSV2 shedding and, at low CD4 counts, severity of clinical manifestations. In terms of HIV acquisition, HSV2 can cause ulcers and microulcerations, and GUD has been associated with a 7–11-fold risk of HIV acquisition in cohort studies. In a meta-analysis of the epidemiological literature of HSV2 and the risk of HIV infection, cohort and nested case–control studies showed an increased risk of acquiring HIV in HSV2-seropositive heterosexual men (risk ratio (RR) 2.7, 95% confidence interval (CI) 1.9 to 3.9), men who have sex with men (RR 1.7, 95% CI 1.2 to 2.4), and women from the general population (RR 3.1, 95% CI 1.7 to 5.6). Among high-risk women, RR values ranged widely, and the summary estimate did not show a significant association (RR 1.0, 95% CI 0.5 to 2.0). HIV acquisition risk is highest among those with recent HSV2 infection, which may reflect the higher frequency and severity of herpetic ulcers during the early stages of HSV2.

HSV2 infection may enhance HIV and HSV2 transmission among people with coinfection. HIV RNA has been isolated from herpetic lesions, and clinically recurrent herpes and asymptomatic shedding is associated with transient increases in HIV load in plasma and genital secretions. These findings suggest that HSV2 reactivation may increase HIV infectiousness. Gray et al studied HIV transmission rates per sex act among HIV-discordant monogamous couples in Rakai, Uganda. The two most important risk factors for HIV transmission were the presence of genital ulcers and higher HIV plasma load. Most GUDs in Rakai (87% of all ulcers with known aetiology) were due to HSV2.

Genital herpes in people with HIV infection

Although clinical observations suggest that patients with HIV have more frequent and prolonged episodes, few studies have examined the effect of HIV on the natural history of HSV2 infection. The influence of immunodeficiency on the clinical expression of HSV2 infection is complex, and although impaired T cell function is expected to increase HSV2 re-activation rates and shedding, it may also reduce the host inflammatory response, and therefore the clinical expression of HSV2 infection. Consistent with this hypothesis, HSV2 infection has been included as a possible manifestation of the immunoreconstitution syndrome induced by highly active antiretroviral therapy.

Virus detection in genital swabs

Virus isolation in cell culture has long been considered the diagnostic gold standard for HSV. Specificity is virtually 100%, but levels of virus shedding, specimen quality and transport conditions influence sensitivity. Test performance declines with time since the onset of lesions and is on average 52–93% for vesicles, 41–72% for ulcers and 19–27% for crusted lesions. PCR increases the sensitivity of culture by 11–75%, and it has recently been recommended as the new diagnostic gold standard for genital herpes. Additional methods include detection of viral antigen by direct immunofluorescence assay using fluorescein-labelled monoclonal antibodies on smears, or by enzyme immunoassay on swabs. Immunofluorescence is expensive and shows lower sensitivity (74%) and specificity (83%) than virus culture. Antigen enzyme immunoassay shows >95% specificity and 62–100% sensitivity relative to virus culture.

HSV2-specific serology

Commercially available assays to detect antibodies to HSV2-specific glycoprotein gG-2 have markedly improved serological diagnosis of HSV2 infection over the past 10 years. These tests have been evaluated in industrialised countries, and their sensitivity against western blot ranged from 93% to 100%, and the specificity ranged from 95% to 100%. Recent evaluations of

![Figure 1](https://www.stijournal.com)
### Table 1  Review of aetiology of genital ulcer disease in Africa, Asia and Latin America

<table>
<thead>
<tr>
<th>City, country, reference</th>
<th>Year</th>
<th>Population</th>
<th>TP</th>
<th>HD</th>
<th>HSV</th>
<th>LGV</th>
<th>Mixed aetiology</th>
<th>No detection</th>
<th>HSV2</th>
<th>Syphilis</th>
<th>HIV</th>
<th>Laboratory techniques</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaborone, Botswana</td>
<td>1993</td>
<td>108 M, F</td>
<td>1  (1)</td>
<td>27 (25)</td>
<td>25 (23)</td>
<td>2 (2)</td>
<td>5 (5)</td>
<td>58 (54)</td>
<td>NR</td>
<td>56 (52)</td>
<td>40 (37)</td>
<td>TP dark field, HD, and HSV culture, syphilis serology RPR-TPHA, CT antibodies MIF, HIV-ELISA</td>
</tr>
<tr>
<td>Gaborone, Francistown and Selela, Phikwe, Botswana</td>
<td>2002</td>
<td>137 M, F</td>
<td>2 (21)</td>
<td>1 (1)</td>
<td>80 (58)</td>
<td>NR</td>
<td>0 (0)</td>
<td>54 (39)</td>
<td>NR</td>
<td>7 (5)</td>
<td>72 (74)</td>
<td>TP, HD, and HSV MPCR, syphilis serology RPR-TPHA, HIV-ELISA</td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1985</td>
<td>89 F</td>
<td>11 (12)</td>
<td>43 (48)</td>
<td>2 (2)</td>
<td>3 (3)</td>
<td>31 (35)</td>
<td>NR</td>
<td>24 (27)</td>
<td>NR</td>
<td>TP dark field, HD, and HSV culture; syphilis serology RPR-MHA-TP, HIV-ELISA</td>
<td></td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1985</td>
<td>115 M</td>
<td>3 (3)</td>
<td>81 (70)</td>
<td>10 (9)</td>
<td>NR</td>
<td>21 (18)</td>
<td>37 (32)</td>
<td>17 (15)</td>
<td>19 (17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1990–1</td>
<td>168 M, F</td>
<td>NR</td>
<td>56 (33)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>24 (14)</td>
<td>NR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1995–7</td>
<td>245 M, F</td>
<td>89 (36)</td>
<td>111 (45)</td>
<td>49 (20)</td>
<td>NR</td>
<td>39 (16)</td>
<td>36 (15)</td>
<td>NR</td>
<td>69 (28)</td>
<td>88 (36)</td>
<td></td>
</tr>
<tr>
<td>Nairoobi, Kenya</td>
<td>1993–4</td>
<td>105 M, F</td>
<td>23 (23)</td>
<td>56 (56)</td>
<td>26 (26)</td>
<td>7 (7)</td>
<td>17 (17)</td>
<td>6 (6)</td>
<td>54 (54)</td>
<td>25 (25)</td>
<td>37 (36)</td>
<td></td>
</tr>
<tr>
<td>Blantyre, Malawi</td>
<td>1993</td>
<td>778 M</td>
<td>136 (20)</td>
<td>204 (26)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>129 (17)</td>
<td>445 (57)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lilongwe, Malawi</td>
<td>1998–9</td>
<td>137 M, F</td>
<td>5 (4)</td>
<td>41 (30)</td>
<td>47 (34)</td>
<td>NR</td>
<td>2 (1)</td>
<td>46 (34)</td>
<td>107 (80)</td>
<td>12 (9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antananarivo, Madagascar</td>
<td>1997</td>
<td>196 M</td>
<td>56 (29)</td>
<td>64 (33)</td>
<td>19 (10)</td>
<td>NR</td>
<td>6 (3)</td>
<td>62 (32)</td>
<td>NR</td>
<td>59 (33)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Kigali, Rwanda</td>
<td>1986</td>
<td>210 M</td>
<td>63 (30)</td>
<td>36 (34)</td>
<td>37 (18)</td>
<td>29 (14)</td>
<td>29 (14)</td>
<td>75 (36)</td>
<td>NR</td>
<td>81 (39)</td>
<td>124 (59)</td>
<td></td>
</tr>
<tr>
<td>Kigali, Rwanda</td>
<td>1990–2</td>
<td>395 M, F</td>
<td>110 (28)</td>
<td>115 (29)</td>
<td>89 (23)</td>
<td>NR</td>
<td>46 (12)</td>
<td>127 (32)</td>
<td>NR</td>
<td>289 (73)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dakar, Senegal</td>
<td>1992</td>
<td>39 M, F</td>
<td>6 (15)</td>
<td>22 (56)</td>
<td>5 (13)</td>
<td>NR</td>
<td>4 (10)</td>
<td>10 (26)</td>
<td>NR</td>
<td>52 (47)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Carletonville, South Africa</td>
<td>1992</td>
<td>240 M</td>
<td>25 (10)</td>
<td>147 (61)</td>
<td>7 (3)</td>
<td>15 (6)</td>
<td>14 (6)</td>
<td>29 (12)</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carletonville, South Africa</td>
<td>1993–4</td>
<td>232 M</td>
<td>24 (10)</td>
<td>161 (69)</td>
<td>40 (17)</td>
<td>NR</td>
<td>17 (7)</td>
<td>25 (11)</td>
<td>NR</td>
<td>110 (48)</td>
<td>126 (54)</td>
<td></td>
</tr>
<tr>
<td>Carletonville, South Africa</td>
<td>1998</td>
<td>186 M</td>
<td>23 (12)</td>
<td>94 (51)</td>
<td>67 (36)</td>
<td>NR</td>
<td>31 (17)</td>
<td>39 (21)</td>
<td>NR</td>
<td>72 (40)</td>
<td>108 (59)</td>
<td></td>
</tr>
<tr>
<td>Cape Town, South Africa</td>
<td>1993–4</td>
<td>180 M</td>
<td>59 (33)</td>
<td>31 (17)</td>
<td>43 (24)</td>
<td>NR</td>
<td>6 (3)</td>
<td>54 (30)</td>
<td>169 (86)</td>
<td>61 (47)</td>
<td>24 (13)</td>
<td></td>
</tr>
<tr>
<td>Johannesburg, South Africa</td>
<td>1993–4</td>
<td>159 M</td>
<td>19 (10)</td>
<td>34 (21)</td>
<td>78 (49)</td>
<td>NR</td>
<td>6 (4)</td>
<td>34 (21)</td>
<td>78 (50)</td>
<td>58 (46)</td>
<td>76 (48)</td>
<td></td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1984</td>
<td>100 M</td>
<td>23 (23)</td>
<td>40 (40)</td>
<td>9 (9)</td>
<td>NR</td>
<td>11 (11)</td>
<td>41 (41)</td>
<td>97 (97)</td>
<td>35 (35)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1988–9</td>
<td>100 M</td>
<td>42 (42)</td>
<td>34 (34)</td>
<td>10 (10)</td>
<td>6 (6)</td>
<td>14 (14)</td>
<td>24 (24)</td>
<td>NR</td>
<td>44 (44)</td>
<td>5 (5)</td>
<td></td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1988–9</td>
<td>100 F</td>
<td>40 (40)</td>
<td>14 (14)</td>
<td>18 (18)</td>
<td>6 (6)</td>
<td>13 (13)</td>
<td>20 (20)</td>
<td>NR</td>
<td>49 (49)</td>
<td>3 (3)</td>
<td></td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1993–4</td>
<td>199 M</td>
<td>29 (15)</td>
<td>106 (53)</td>
<td>72 (34)</td>
<td>NR</td>
<td>33 (17)</td>
<td>29 (15)</td>
<td>81 (49)</td>
<td>39 (23)</td>
<td>115 (58)</td>
<td></td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>2000–1</td>
<td>587 M, F</td>
<td>85 (14)</td>
<td>57 (10)</td>
<td>284 (48)</td>
<td>63 (11)</td>
<td>63 (11)</td>
<td>156 (27)</td>
<td>NR</td>
<td>441 (75)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dar es Salaam and Mbaya, Tanzania</td>
<td>1999</td>
<td>102 M, F</td>
<td>1 (1)</td>
<td>21 (21)</td>
<td>59 (58)</td>
<td>NR</td>
<td>9 (9)</td>
<td>39 (38)</td>
<td>NR</td>
<td>15 (15)</td>
<td>50 (48)</td>
<td></td>
</tr>
</tbody>
</table>
these tests have raised concerns about lower specificity with African sera. These findings could be due to problems of cross-reactivity, or reflect the fact that some tests detect HSV2 seroconversions earlier than others, including western blot. It has been recommended that the threshold for calculating positive results should be increased as a way of improving specificity, although this may also reduce sensitivity in early infection.

### The role of routine laboratory investigations

The cost:benefit ratio of adopting virus detection and HSV2-specific serology for routine management of patients attending STI clinics in developing countries remains currently uncertain. Given that the clinical diagnosis of genital herpes is typically unreliable, a laboratory confirmation is desirable. Antigen enzyme immunosassay may be an option for resource-limited settings, as assays are commercially available and easy to perform, but the test is expensive and its sensitivity is suboptimal. Although PCR allows less stringent conditions for sample storage and transport than virus culture and can be highly automated, it requires sophisticated laboratory equipment, high-level technical expertise and strict quality control. These conditions combined make PCR a difficult diagnostic option in most resource-limited settings. Centralised laboratory facilities may be one method of providing testing. Although results may not be available for immediate patient management, important information is gained on local epidemiology of GUD and the validity of syndromic approaches to GUD management, thus assisting programme managers in evidence-based decision making.

Similar considerations apply to the use of HSV-specific serology for screening purposes, although the tests are expensive and in many settings infection with HSV2 is nearly universal among patients with GUD. The strongest argument in favour of screening is that HSV2-seropositive people can be counselled about the increased risk of HIV acquisition. Thus, the scope for using HSV2 serology to detect infected people may grow in developing countries should evidence from ongoing studies support the use of antiviral treatment against HSV2 as a strategy for HIV prevention. In this case, serological screening could be considered to identify people coinfected with both viruses who could benefit from suppressive anti-HSV2 treatment. This might be especially important for couples with discordant HSV2/HIV serostatus.

### CURRENT TREATMENT STRATEGIES

#### Antiviral treatment

For bacterial STI, treatment is usually short and aimed at both reducing the duration and severity of symptoms and eliminating the aetiological agent. For viral STI such as herpes, treatment can be either short and episodic, which will reduce the severity and duration of symptomatic recurrences, or longer-term suppressive treatment, which will reduce the number and severity of symptomatic episodes and asymptomatic shedding. Episodic treatment in recurrent episodes reduces pain, decreases time to ulcer healing by 1–2 days and reduces HSV2 shedding by 1–2 days, although it has no effect on recurrence rates. For suppressive treatment with aciclovir can prevent or delay 80% of recurrences, and reduce clinical and subclinical shedding by >90%. Aciclovir's pharmaceutical patent has recently expired and the drug is now available in generic form from nine manufacturers in seven countries worldwide for <US$0.20 per tablet.
Addition of aciclovir to the syndromic management of GUD

Previous WHO guidelines for the treatment of GUD were concerned with bacterial aetiologies and provided no suggestions for effective treatment for genital herpes. Owing to the observed increase in the worldwide prevalence of HSV2 infection, the WHO now recommends giving antiviral therapy to patients with genital herpes who meet the criteria for treatment. These recommendations are based on the fact that HSV2 infection is becoming more common, and herpes is responsible for most cases of GUD. Treatment for these bacterial infections will probably have to continue for several years until syphilis and chancroid are eliminated. The WHO is currently assessing a 5-year control initiative for genital ulcers, with the goal of eliminating chancroid and reducing the prevalence of syphilis. Several trials are under way to evaluate the effect of antiviral therapy on the transmission of HSV2 and HIV infections. The first trial to assess the cost effectiveness of this strategy needs to be determined.

Table 2  Research Initiatives Evaluating HSV-2 and HIV-1 Interactions and the Use of Anti-Herpes Therapy to Reduce Acquisition and Transmission of HIV-1

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Population</th>
<th>Outcome</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSV-2 suppressive treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acyclovir treatment to prevent HIV-1 acquisition</td>
<td>1600 HIV-1-negative HSV-2-positive women, in Zimbabwe, Zambia and Johannesburg, and, 1600 high-risk, HIV-1-negative HSV-2-positive men who have sex with men in Peru and United States</td>
<td>HIV-1 incidence</td>
<td>Ongoing until the end of 2006</td>
</tr>
<tr>
<td>Acyclovir treatment to prevent HIV-1 acquisition and reduce HIV-1 vaginal shedding</td>
<td>1300 HSV-2-positive high risk women, both HIV-1-positive and negative in Tanzania</td>
<td>HIV-1 incidence among initially HIV-, and HSV-2 &amp; HIV-1 vaginal shedding among HIV-1-positive</td>
<td>Ongoing until 2007</td>
</tr>
<tr>
<td>Acyclovir treatment to prevent HIV-1 transmission</td>
<td>3646 HIV-1 discordant couples (HIV-1-positive partner is also HSV-2-positive and has a CD4 count of 250 cells/mm³) in Botswana, Kenya, Zambia, Rwanda, Tanzania and Uganda</td>
<td>HIV-1 incidence in HIV-1-negative partner</td>
<td>Ongoing until 2007</td>
</tr>
<tr>
<td>Valacyclovir treatment to reduce HIV-1 shedding</td>
<td>140 HIV-1-positive HSV-2-positive women in Burkina Faso</td>
<td>HIV-1 cervico-vaginal and plasma viral loads</td>
<td>Finished recruitment October 2005</td>
</tr>
<tr>
<td>Acyclovir treatment to reduce HIV-1 shedding</td>
<td>300 HIV-1-positive HSV-2-positive women in South Africa</td>
<td>HIV-1 and HSV-2 cervico-vaginal and plasma viral loads</td>
<td>Finished recruitment in May 2006</td>
</tr>
<tr>
<td>Acyclovir treatment to reduce HIV-1 shedding</td>
<td>67 HIV-1 and HSV-2 infected women, Chiang Rai, Thailand</td>
<td>HIV-1 and HSV-2 cervico-vaginal shedding</td>
<td>Finished recruitment in 2006</td>
</tr>
<tr>
<td>Acyclovir treatment to reduce HIV-1 shedding</td>
<td>380 HIV-1/HSV-2-positive high-risk women in Tanzania (part of the second study listed above)</td>
<td>HIV-1 and HSV-2 cervico-vaginal and plasma viral loads</td>
<td>Finished follow-up in October 2005</td>
</tr>
<tr>
<td>HSV-2 episodic treatment as part of syndromic management of genital ulcer disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acyclovir treatment for 5 days</td>
<td>600 men HIV-1-positive and negative with genital ulcers in South Africa</td>
<td>Ulcer healing, HIV-1 ulcer healing</td>
<td>Ongoing until the end of 2006</td>
</tr>
<tr>
<td>Acyclovir treatment for 5 days</td>
<td>410 women HIV-1-positive and negative with genital ulcers in Ghana and Central African Republic</td>
<td>Ulcer healing, HIV-1 cervico-vaginal and ulcer shedding</td>
<td>Finished recruitment in October 2005</td>
</tr>
<tr>
<td>Acyclovir treatment for 5 days</td>
<td>400 men and women HIV-1 positive and negative with genital ulcers in Malawi</td>
<td>Ulcer healing, HIV-1 vaginal, ulcer and semen shedding</td>
<td>Ongoing until July 2006</td>
</tr>
</tbody>
</table>

Treatment of genital herpes for the prevention of acquisition and transmission of HIV

As antiviral treatment can reduce virus shedding and viral loads, it has been hypothesised that they also reduce transmission of HSV2 and HIV infections. The first trial to assess the effect of antiviral treatment on the heterosexual transmission of a viral infection has been completed recently. Provision of suppressive treatment was shown to reduce HSV2 transmission. A multicentre study among monogamous, heterosexual, HSV2-discordant couples found that a once-daily suppressive dose of valaciclovir reduced the incidence of symptomatic genital herpes among the uninfected by 77% and the overall risk of transmission by 50%.

Several trials are under way to evaluate the effect of antiviral treatment in reducing HIV transmission and acquisition. These trials are considering the following public health issues:

1. Reducing the enhancing effect of HSV2 on HIV, by episodic treatment of genital herpes in populations with high risk of transmission or acquisition of HIV (ie patients with STI)
2. Suppression of HSV2, to reduce susceptibility to HIV among HIV-negative, HSV2-seropositive people
3. Suppression of HSV2, to reduce infectiousness of HIV among people with HIV/HSV2 coinfection. Encouraging data were recently presented by Nagot et al showing that suppressive treatment with valaciclovir reduced delayed healing of ulcers and multiple recurrences are already an increasing problem. These patients would greatly benefit from suppressive treatment.

Trials are currently under way in South Africa, Ghana and Malawi to evaluate the incorporation of aciclovir into the syndromic management of GUD and its effect on reduction of pain, ulcer healing and HIV shedding from ulcers (table 2). The cost effectiveness of this strategy needs to be determined.
HIV vaginal shedding and HIV plasma load among women with dual infections.

**OTHER HERPES INTERVENTIONS**

**Condom use**

Few studies have evaluated the protection provided by condoms against genital herpes. Most cross-sectional studies have failed to show an association and even suggest increased risk among men using condoms, probably because condom use is a marker of high-risk relationships. One prospective study reported protection from condom use only among women. A more recent study showed that participants reporting more frequent condom use (condom use for >75% of sexual acts) were at a lower risk of acquiring HSV2 (hazard ratio 0.7, 95% CI 0.6 to 0.9).

**HSV2 vaccines**

Although animal studies on vaccination strategies to prevent genital and neonatal herpes may be promising, clinical trials of HSV2 vaccines in humans have failed to prove efficacy. In a recent study, an HSV2 glycoprotein D vaccine using alum as adjuvant induced protection from clinical disease (73%) and overall HSV2 transmission (about 40%). By contrast, no protective efficacy was observed with a similar vaccine based on the viral glycoproteins B and D and using MF59 as adjuvant. The protective effect of the MPL vaccine was seen only in women who were HSV1 and HSV2 seronegative, and there was no protection among men or among HSV1-seropositive women. The partial efficacy was shown to be related to the induction of T cell immunity with a Thelper 1 profile. The vaccine is currently being evaluated in a large multicentre trial targeting pre-pubertal girls.

**DISCUSSION**

HSV2 is highly prevalent in most regions, especially those experiencing HIV epidemics, and it has become the most important cause of GUD worldwide. In addition to the suffering and expense incurred by people with HSV2 infections, substantial data support an important role of HSV2 in facilitating HIV transmission and acquisition.

As with all STIs, the most cost-effective intervention is primary prevention. However, STI control has been successful only in a limited number of settings, and primary prevention programmes have obstacles of acceptance and effectiveness among populations who are both vulnerable and at risk. Given the epidemiology of HSV2 acquisition as primarily an incident infection among young people, we should undoubtedly be focusing primary prevention efforts on this age group, especially in resource-poor settings where incidence and prevalence remain highest. Primary prevention should include delaying sexual debut among adolescents and reducing the number of sexual partners. Male condoms protect against HSV2 less effectively than against HIV, but still have some efficacy. Given the strong efficacy of condoms in protecting against HIV and other STIs, promotion of condom use should always be included in any STI prevention effort.

Once infected with HSV2, a lifelong viral infection requires different management strategies compared with managing "one-off" bacterial infections. Although conventional wisdom may have mitigated against the cost effectiveness of trying to control a recurrent infection in resource-poor settings, increasing evidence of the interaction between HSV2 infection and the risk of HIV transmission, and the increasing contribution of HSV2 to the burden of GUD, has raised the salience of HSV2. Whether providing suppressive or episodic antiviral treatment, more attention should be focused on ensuring that people infected with HSV2 have access to appropriate and effective care. Services should be part of a prevention package including HIV testing and counselling to all patients with STI, counselling to improve recognition of herpes symptoms, early initiation of episodic aciclovir treatment and counselling on condom use, and abstaining from sexual intercourse during herpes outbreaks.

Prevention and treatment strategies should be first targeted at people with genital herpes lesions. Although these may be a small proportion of those who are HSV2 seropositive, people with lesions are at highest risk of transmitting the virus. Questions on the effect of antithromboprophylaxis in preventing HIV transmission and acquisition remain unanswered. Ongoing trials will assist in filling these knowledge gaps and will provide the evidence required to design new interventions for herpes. In countries in sub-Saharan Africa, where the prevalence of HSV2 is extremely high, the provision of aciclovir for people with genital ulcers who are being treated syndromically might represent the most cost-effective and easiest means to implement a strategy for HIV prevention.

While the inclusion of herpes treatment in syndromic management is further evaluated on the basis of current WHO and US STI management recommendations, aciclovir should be made available for patients with primary herpes (although hard to identify in developing countries), those with severe episodes, immunosuppressed patients and patients with frequent recurrences. Developing countries should also consider adding aciclovir to the essential drug list. Further, with the help of WHO, aciclovir should be made available and affordable in developing countries.

**REFERENCES**


www.stijournal.com


